Nektar Therapeutics (NAS:NKTR)
$ 1.07 -0.11 (-9.32%) Market Cap: 197.37 Mil Enterprise Value: 81.43 Mil PE Ratio: 0 PB Ratio: 3.96 GF Score: 59/100

Q2 2022 Nektar Therapeutics Earnings Call Transcript

Aug 04, 2022 / 09:00PM GMT
Release Date Price: $4.42 (-1.12%)
Operator

Good afternoon, and welcome to the Nektar Therapeutics Second Quarter Financial Results Conference Call. (Operator Instructions) Please note, this event is being recorded.

I would now like to turn the conference over to Vivian Wu from Nektar Investor Relations. Please go ahead.

Vivian Wu

Thank you, Chad, and good afternoon, everyone. Thank you for joining us today. With us on the call are Howard Robin, our President and CEO; Dr. Jonathan Zalevsky, our Chief of Research and Development; Jill Thomsen, our Chief Financial Officer; and Brian Kotzin, our Chief Medical Officer.

On today's call, we expect to make forward-looking statements regarding our business, including statements regarding the therapeutic potential of and future development plans for drug candidates and research programs; the timing of the intention, initiation of clinical studies and the availability of clinical data for drug candidates; the timing and plans for future clinical data presentations; information, future development plans or success of our collaboration arrangements; the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot